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Dr D. Adams (New York, NY). I would like to disclose that I am
a coinventor of the Physio II (Edwards Lifesciences, Irvine, Calif)
and ischemic mitral regurgitation annuloplasty rings and have con-
sulting and royalty agreements with Edwards. Dr DiBardino, I en-
joyed your presentation and congratulate you on this effort to
provide us with the long-term follow-up of Dr Cohn’s impressive se-
ries of valve reconstruction in more than 1500 patients performed
over a 36-year period. The fact that the overall mortality in this series
averaged 1.3%with no significant difference in risk regardless of de-
cade of surgery is a testament to Dr Cohn’s skill and leadership of
one of the most outstanding programs in our specialty. My first ques-
tion relates to the completeness of your echo and reoperation follow-
up. Death is a relatively easy variable to confirm in a retrospective
analysis. Reoperations and particularly recurrence of mitral regurgi-
tation rates are more challenging. Please give us a sense of how con-
fident you are in the latter 2 event rates you present?
Dr DiBardino. Thank you, Dr Adams, for your question, and it
is nice to be graduating from a program and to see so many people
who have come before me do such great things in the field. In
regard to the completeness of the data, the survival data are 98%
complete largely because of the use of the death index, as you
acknowledge, and that is certainly the easiest hard end point to
achieve. The reoperation data are 83% complete; data for the myx-
omatous group are approximately 90% complete. The data are not
perfect, and we ran into several problems. One is, of course,
patients with international and even national referrals are tough
to investigate. The other problem is when you try to look at it
over 36 years, patients who died, say, at 20 years postoperatively
10 years ago, it might be possible to identify whether they had a re-
operation before death, and I only included patients I was 100%
sure of a hard and fixed end point. So the 83% we had is the best
we could do. I think it fairly represents the patients who were at
risk. Now, the echocardiogram data are, by far, the toughest of
the 3 to get, for many of the same reasons. The mean of the echo
data I presented here is only 4 years. The patients who are in
good functional status, it seems, don’t like to get echocardiograms
much past that, and that was a problem I ran into trying to contact
these patients and get these echo follow-ups. So that is the toughest
one to get, and it is about two thirds. We hoped to do a lot better.
Dr Adams. In your degenerative group, your most common
strategy for bileaflet prolapse is a posterior leaflet repair and ring
annuloplasty. A true anterior leaflet prolapse is actually not cor-
rected by posterior leaflet or annular surgery. Please clarify exactly
what you mean in your article by anterior leaflet involvement in
these patients. Was this assessed by preoperative echocardiography
or intraoperative valve analysis?
Dr DiBardino. That is an excellent point. The 2 superimposed
curves I showed, one is for posterior only and the other is for ante-
rior. This is by intraoperative note review. So these would be
mostly by the saline test. Yes, they reflect sort of the gestalt of
the echo in the surgeon’s mind going into the operating room and
especially the intraoperative transesophageal echocardiogram be-
fore repair, but they really were as described, by saline test, and
your point is very well taken. What this really reflects is not an
echo finding of true bileaflet prolapse but a tendency toward pro-
lapse, chordal elongation, and so forth, just as you say. And going
back so many years over so many patients, because that was theThe Journal of Thoracic and Cmost consistent way I had of identifying what the valve ‘‘looked
like,’’ it is what I went with, and that reflects, as you say, the types
of repairs the patients underwent. So that is absolutely right. This is
an intraoperative inspection.
Dr Adams. I think that will be important to clarify in your arti-
cle.
My next question is about rheumatic repair and degenerative re-
pair. The survival was similar but the reoperation rate was higher in
the rheumatic group. How do you reconcile that?
Dr DiBardino. The patients who were followed for rheumatic
disease were followed for a lot longer. The first operation for ische-
mic disease was in 1981, and the first operation for rheumatic dis-
ease was in 1972. So the follow-up is longer. Also, the reoperation
data on the patients with FMR are somewhat tainted by the fact that
many of them did not survive the first 10 years. So they fall out of
play in the Kaplan–Meier analysis.
Dr Adams. Your 10-year freedom of reoperation was only 84%
in the anterior leaflet repair subgroup. In your article, you infre-
quently use polytetrafluoroethylene neochordae or chordal transfer
or leaflet transfer, which are commonplace in most centers today.
Can you clarify your current strategy to repair anterior leaflet pro-
lapse, and do you have echo data regarding recurrence of mitral
regurgitation in this retrospective subgroup?
DrDiBardino. That is a very keen observation. You are right. In
fact, chordal transfer has never been something that Dr Cohn has
used. I can’t think of a single case identified in this series. He
just never liked it. The anterior polytetrafluoroethylene (Gore-
Tex; WL Gore & Associates Inc, Newark, Del) chordal resuspen-
sion has been used, as you say, infrequently compared with most
centers. It is not something that we prefer if we can get away with-
out doing it. Commissuroplasty is used commonly in those patients
whom we identified as having anterior prolapse toward 1 commis-
sure, and we reported in 2006 about our use of the Alfieri stitch,
mostly prophylactically when high-risk SAM is identified, but
that also fixes that kind of a problem.
In terms of isolated echo data, I do not have isolated echo data
broken down by cause.
Dr Adams. Can you clarify your current approach to patients
with ischemic mitral regurgitation given your high reoperation rates
during long-term follow-up? Have you changed your ring or repair
strategy currently or are you doing more replacements in this sub-
group?
Dr DiBardino. The answer to your question is that the ring
designs influenced what we saw over the years. When you look
at this reoperation rate, you are looking into the past in terms that
are looking at patients who received mostly C-band Cosgrove
rings. Dr Bolling is probably about to vomit here listening to
this, but it is true. And I think that the ring designs change, and
certainly we are applying more of the GeoForm and Physio rings
(Edwards Lifesciences), and hopefully you will show us some
data on the Physio II that is more promising.
Dr S. Bolling (Ann Arbor, Mich). Dan, I rise to congratulate you,
your institution, and Dr Cohn on a fantastic series. I have one
specific question. Your mortality by decade was no different, which
is a testament to the excellent care for these patients at your institu-
tion. I know your follow-up for reoperation rate is only 83% com-
plete by echo, but were you able to identify factors that influenced
your reoperation rate? Obviously our surgical techniques over theardiovascular Surgery c Volume 139, Number 1 83
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identify something, the absence of a ring or no ring or some other
factor, that led us to improve our reoperation rates?
Dr DiBardino.We at the Brigham and many others have shown
that the absence of a ring was an independent predictor of reopera-84 The Journal of Thoracic and Cardiovascular Surgetion for MV disease. That remains true, and I am in the process of
trying to perform a more formal analysis. I am trying to develop
a scoring system looking at predictors of reoperation. It is still
not ready for prime time yet. I hope to be able to speak about it
sometime in the future.ry c January 2010
